Peak Oxygen Uptake in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Meta-Analysis.
Franklin, John Derek, Atkinson, Greg, Atkinson, Janet M et al. · International journal of sports medicine · 2019 · DOI
Quick Summary
This research review analyzed 32 studies comparing how much oxygen people with ME/CFS can use during maximum exercise compared to healthy people. On average, people with ME/CFS used about 5 milliliters less oxygen per kilogram of body weight per minute than healthy controls—a meaningful difference that likely affects real-world functioning. This reduced oxygen capacity is one of the measurable physical differences between ME/CFS patients and healthy individuals.
Why It Matters
Reduced oxygen uptake capacity is an objective, measurable physiological marker that validates ME/CFS as a real medical condition with demonstrable physical impairment. This finding supports the use of cardiopulmonary exercise testing in clinical assessment and helps quantify the severity of functional limitation patients experience. Understanding this biological abnormality may guide rehabilitation approaches and help distinguish ME/CFS from other conditions.
Observed Findings
ME/CFS patients showed a pooled mean VO₂peak reduction of 5.2 ml·kg⁻¹·min⁻¹ compared to healthy controls (95% CI: 3.8–6.6).
Between-study variability was substantial (Tau = 3.4 ml·kg⁻¹·min⁻¹), indicating considerable differences in effect sizes across the 32 included studies.
The 95% prediction interval (−1.9 to 12.2 ml·kg⁻¹·min⁻¹) suggests that most future studies would find effects favoring controls.
There was an 88% probability that future studies would detect differences exceeding the minimum clinically important difference of 1.1 ml·kg⁻¹·min⁻¹.
Inferred Conclusions
ME/CFS patients have substantially and clinically meaningfully reduced oxygen uptake capacity compared to healthy controls.
The large between-study heterogeneity suggests variability in disease severity, patient populations, or testing protocols across studies.
Reduced VO₂peak is a consistent, objectively measurable physiological feature of ME/CFS that appears robust across multiple independent investigations.
Remaining Questions
What specific physiological mechanisms underlie the reduced VO₂peak—cardiac output, oxygen extraction, mitochondrial function, or muscle dysfunction?
Does VO₂peak correlate with symptom severity, functional disability, or post-exertional malaise in individual patients?
What This Study Does Not Prove
This meta-analysis does not establish the cause of reduced VO₂peak—whether it results from cardiac dysfunction, mitochondrial impairment, muscle pathology, or another mechanism remains unclear. The study is correlational and cannot prove that low oxygen uptake causes fatigue or other ME/CFS symptoms. It also does not address whether VO₂peak changes over time or whether specific treatments can improve this measure.
Can VO₂peak be improved through specific interventions, or is the impairment stable and trait-like in ME/CFS?
Why was there such substantial heterogeneity between studies, and do patient characteristics, disease duration, or testing protocols explain these differences?